Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

BACKGROUND: Blinatumomab, a bispecific monoclonal antibody construct that enables CD3-positive T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) blasts, was approved for use in patients with relapsed or refractory B-cell precursor ALL on the basis of single-group tr...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:N Engl J Med
Päätekijät: Kantarjian, Hagop, Stein, Anthony, Gökbuget, Nicola, Fielding, Adele K., Schuh, Andre C., Ribera, Josep-Maria, Wei, Andrew, Dombret, Hervé, Foà, Robin, Bassan, Renato, Arslan, Önder, Sanz, Miguel A., Bergeron, Julie, Demirkan, Fatih, Lech-Maranda, Ewa, Rambaldi, Alessandro, Thomas, Xavier, Horst, Heinz-August, Brüggemann, Monika, Klapper, Wolfram, Wood, Brent L., Fleishman, Alex, Nagorsen, Dirk, Holland, Christopher, Zimmerman, Zachary, Topp, Max S.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5881572/
https://ncbi.nlm.nih.gov/pubmed/28249141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1609783
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia